Epilepsy is common in people with intellectual and developmental disabilities (IDD). In
adulthood, patients with IDD and epilepsy (IDD-E) have neurologic, psychiatric, medical …

Patient tolerability is a significant limiting factor in the treatment of epilepsy and adverse
effect profiles often determine drug retention rates. A full appreciation of the behavioral …

The aim of this prospective, multicenter, open-label study was to investigate the efficacy of
levetiracetam (LEV) and determine its effects on cognitive and neuropsychological function …

INTRODUCTION: Levetiracetam (LEV) is a broad spectrum antiepileptic drug (AED) with a
unique mechanism of action. This retrospective audit explores outcomes in patients …

Objectives The aim of this cross‐sectional retrospective study was to assess the tolerability
and efficacy of perampanel in patients with drug‐resistant epilepsy who also suffered from …

Background Approximately one quarter of people with an intellectual disability (PwID) have
epilepsy of whom nearly three-quarters are pharmaco-resistant. There are higher reported …

Introduction: This clinical guidance looks at the specific concerns of delivery of medical
treatment for people with epilepsy and intellectual disability (ID). People with ID have not …

Background Intellectual disability (ID) is relatively common in people with epilepsy, with
prevalence estimated to be around 25%. Surprisingly, given this relatively high frequency …

Abstract Introduction People with Intellectual Disabilities (PwID) are twenty times more likely
than general population to have epilepsy. Guidance for prescribing antiseizure medication …

Los trastornos del neurodesarrollo tienen alta frecuencia en la población en general y se
asocian con frecuencia a la epilepsia. La terminología ha tenido cambios, lo que ha hecho …